Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788 at the 2020 San Antonio Breast Cancer Symposium
- 74% ORR in the Phase 1 HER2-positive Breast Cancer Trial in China and 67% ORR in the Phase 1 HER2 Expressing Pan-tumor Trial in US/AU
- Multiple Global Phase 2/3 Trials to Begin Early 2021
News provided by
Share this article
Share this article
SAN DIEGO, Dec. 10, 2020 /PRNewswire/ Ambrx Inc., a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code, provided a clinical update on their lead program ARX788, a homogeneous and highly stable, site-specific antibody drug conjugate (ADC) targeting HER2 positive cancers.